Lin, Amy M <br/><br/>
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.  [electronic resource] 

 -  BJU international  Oct 2006 
 - 763-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1464-4096 
<br/><br/><label>Standard No.: </label>10.1111/j.1464-410X.2006.06396.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Benzamides<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--blood<br/>Piperazines--adverse effects<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Pyrimidines--adverse effects<br/>Treatment Failure